----item----
version: 1
id: {3F32045C-ADBA-454B-9CBC-FB1FE5D581C4}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/04/17/Jeremy Levins metamorphosis continues as Ovids CEO
parent: {5262FD33-8196-4910-BCB3-3BC76EEBE076}
name: Jeremy Levins metamorphosis continues as Ovids CEO
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 2974b80f-650e-429f-915c-719465955214

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 52

Jeremy Levin's metamorphosis continues as Ovid's CEO
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 50

Jeremy Levins metamorphosis continues as Ovids CEO
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1184

<p>Jeremy Levin, the former CEO of Teva, is continuing his career transformation into biotech by taking up the position of chief executive officer at the private New York-based firm Ovid Therapeutics. Dr Levin was appointed Ovid's chairman last year and will continue to serve in this role. </p><p>Dr Levin <a href="http://www.scripintelligence.com/home/Teva-CEO-quits-amid-board-row-rumors-347726" target="_new">left his most high-profile role</a> as CEO of Israeli firm Teva in October 2013 after just 18 months amid rumors of squabbles at the top. Prior to this he was at Bristol-Myers Squibb for about where he pushed through its "String of Pearls" strategy, and before that spent another five years at Novartis where he was head of global business development and strategic alliances at Novartis. He currently serves on the boards of Biocon and privately-held ZappRx.</p><p>Ovid Therapeutics is focusing on rare and orphan diseases of the brain and aims to become a leading neurology company. It is developing OV-103 (gaboxadol) for Angelman Syndrome which is "Phase II ready" and has forthcoming programs in Lewy body dementia, Dravet syndrome and Prader-Willi syndrome. </p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 295

<p>Jeremy Levin, the former CEO of Teva, is continuing his career transformation into biotech by taking up the position of chief executive officer at the private New York-based firm Ovid Therapeutics. Dr Levin was appointed Ovid's chairman last year and will continue to serve in this role. </p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 50

Jeremy Levins metamorphosis continues as Ovids CEO
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150417T180000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150417T180000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150417T180000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028465
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 52

Jeremy Levin's metamorphosis continues as Ovid's CEO
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{EDF1CA8E-D9CB-49CC-8211-BA71D040812B}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

357855
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042331Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

2974b80f-650e-429f-915c-719465955214
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042331Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
